Actively Recruiting
Functional and Phenotypic Characterization of Monocytes in Myeloproliferative Syndromes
Led by University Hospital, Angers · Updated on 2025-12-08
70
Participants Needed
3
Research Sites
229 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Prospective study for functional and phenotypic characterization of monocytes in philadelphia-negative myeloproliferative neoplasms
CONDITIONS
Official Title
Functional and Phenotypic Characterization of Monocytes in Myeloproliferative Syndromes
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosis of polycythemia vera, essential thrombocythemia, prefibrotic primary myelofibrosis, or primary myelofibrosis according to WHO 2022 criteria
- No prior treatment specific to blood disorders at the time of sampling
- Signed consent to participate in the study
- Consent to be included in the "Malignant Hemopathy" collection of Angers University Hospital and FIMBANK database
You will not qualify if you...
- Not affiliated with a social security scheme or beneficiary of such a scheme
- Having another blood disorder or active cancer at diagnosis
- Under 18 years old at diagnosis
- Unable to consent or without guardian/legal representative agreement
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 3 locations
1
GOUBAND Agathe
Angers, Maine et Loire, France, 49933
Actively Recruiting
2
BESCOND Charles
Cholet, Maine et Loire, France, 49325
Not Yet Recruiting
3
TRUCHAN-GRACZYK Malgorzata
Saumur, Maine et Loire, France, 49400
Not Yet Recruiting
Research Team
A
Agathe GOUBAND, PharmD
CONTACT
U
UH Angers DRCI
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here